Choriogonadotropin Alfa
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Choriogonadotropin Alfa
- Choriogonadotropin alfa: From an Unspecified Original Indication to Peptic Esophagitis
Choriogonadotropin alfa: From an Unspecified Original Indication to Peptic Esophagitis
One-Sentence Summary
Choriogonadotropin alfa is a recombinant human chorionic gonadotropin (hCG) marketed in Singapore as an injectable (Ovidrel), and the registration record compiled for this report does not list an approved indication. The TxGNN model predicts it may be effective for peptic esophagitis, but 0 clinical trials and 0 publications currently support this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration data |
| Predicted New Indication | Peptic esophagitis |
| TxGNN Prediction Score | 98.44% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. From general pharmacology, choriogonadotropin alfa is a recombinant hCG that activates the LH/hCG receptor (LHCGR) to trigger ovulation and support gonadal steroid production.
No plausible mechanistic link to peptic esophagitis was identified. Esophageal inflammation from acid reflux is not known to involve LHCGR signaling. The high score (0.984) is a knowledge-graph prediction and most likely reflects graph proximity rather than a biological rationale. No trials or publications back it up.
The other top predictions show the same pattern. They include postural orthostatic tachycardia syndrome, esophageal disease, Raynaud disease, esophageal ulcer and malformation, and several cardiac conduction disorders (sinoatrial block, sinoatrial node disease, His bundle tachycardia, progressive familial heart block). All of them have no clinical or literature evidence and no identified mechanism. The esophageal and conduction-disorder predictions appear to cluster in the knowledge graph rather than provide independent signals.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13015P | Ovidrel Solution for Injection 250 mcg (Merck Serono S.p.A.) | Injection, solution | Not stated in the registration data |
Safety Considerations
Please refer to the package insert for safety information.
No drug-interaction records were found, and no disease contraindications were identified from the knowledge graph. The absence of records does not demonstrate safety. For the cardiac conduction predictions in particular, a gonadotropin has no known antiarrhythmic effect, so any use there would raise safety questions.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is computational only (L5). No trials or publications support it, and no mechanistic link between LHCGR agonism and esophageal disease was identified. The package insert warnings and contraindications are also unavailable, so safety screening cannot proceed.
To proceed, the following is needed:
- The Singapore package insert, to obtain the approved indication, warnings and contraindications
- Mechanism of action data
- A plausible biological rationale for LHCGR involvement in esophageal mucosal disease, supported by preclinical or literature evidence
- A route and formulation compatibility assessment, since the available product is an injectable
- A re-review of the remaining predicted indications if new evidence emerges
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.